



Pharmacy Friday

Brief pearls related to acute care pharmacology and evidence-based medicine

Other pearls found at:

- www.pharmacyfriday.com



Management of Acute Gout in the ED

Introduction

1. Acute gout is common inflammatory arthritis in the adult US population.
2. Gout results from inflammation caused by precipitation of uric acid crystals from supersaturated extracellular fluid.
3. The ACR guidelines recognize NSAIDs, corticosteroids, and colchicine as first-line monotherapy for the treatment of gout.

Pharmacology				
Properties	Naproxen	Prednisone	Triamcinolone	Colchicine
Dose	750 mg orally followed by 250-500 mg every 8 hours until the attack has subsided	40 mg/day for 3 to 5 days, with or without a taper)	20-40 mg for the knee and 5 to 10 mg for smaller joints	1.2 mg PO x 1 followed by 0.6 mg an hour later*
Administration	Oral	Oral	Intra-articular	Oral
PK/PD	Onset: 0.5- 1 hr Duration: up to 12 hrs Renal Excretion: 95 %	Onset: 1-2 hr Elimination ½ life 2-3 hr Renal Excretion: >95%	Onset: 12-24 hr Duration: up to 30 days Renal Excretion: 75%	Onset: 0.5-2 hr Elimination ½ life 27-31 hr Renal Excretion: 45-65%
Adverse Effects	Edema, GI discomfort, headache, dizziness, renal dysfunction	Hypertension, fluid retention, hyperglycemia, disturbance in mood	Headache, injection site pain, influenza-like illness, pharyngitis	GI discomfort, diarrhea, nausea, neuromyopathy, and vomiting
Drug Interactions and warnings	Consider against in patients with high bleeding risk, peptic ulcer disease, heart failure, dehydration, and renal impairment.	Warning with oral contraceptives, CVD, diabetes, GI problems, psychiatric disorders, and live vaccines	Warning if considering joint sepsis , and in patients with diabetes, CVD, GI problems or psychiatric disorders	Drug interaction with CYP3A4 or P-glycoprotein inhibitors. Warning in patients with hematologic, renal, and hepatic insufficiency
Location in GHS	Zone 1,2, 3 + Trauma	Zone 1,2, 3 + Trauma	Main Inpatient Pharmacy	Zone 1,2, 3 + Trauma
Comments	It is critical that therapy is initiated within 24 hours of acute gout attack onset		ACR guidelines recommend intraarticular or oral corticosteroids if only one or two joints are involved	ACR guideline recommends drug started within 36 hours of attack onset

*renal and hepatic dose adjustments

Alternative Agents in Acute Gout			
NSAIDs	Corticosteroids	Interleukin-1 inhibitors	Other Therapies
Ibuprofen PO 400-800 mg three to four times daily	Prednisone PO 0.5 mg/kg equivalent daily for 5-10 days followed by discontinuation Oral methylprednisolone dose pack may be considered	Anakinra (Kineret) 100 mg SC daily for 3 days	ACTH 40 units IM or SC every 72 hours
Indomethacin PO 50 mg three times daily	Triamcinolone acetonide 60 mg IM once followed by oral prednisone or prednisolone	Canakinumab (Ilaris) Single dose 150 mg SC	Local ice application is the most effective non-pharmacologic therapy
Celecoxib PO 800 mg followed by 400 mg on day one then 400 mg twice daily for 1 week	Methylprednisolone 100 mg IM once followed by oral prednisone or prednisolone		Local or regional anesthetic blocks are a potential adjunctive therapy

Monotherapy	Combination Therapy	Elderly ± Multiple Comorbidities	Renal insufficiency	NPO
<ul style="list-style-type: none"> • NSAID • Systemic Corticosteroid • Colchicine 	<ul style="list-style-type: none"> • Colchicine + NSAID • Colchicine+ Oral Corticosteroid • Intraarticular steroid +oral colchicine, NSAID, or corticosteroid 	<ul style="list-style-type: none"> • Corticosteroids > NSAIDS (particularly indomethacin) or Colchicine 	<ul style="list-style-type: none"> • Intraarticular, oral, or parenteral glucocorticoids 	<ul style="list-style-type: none"> • ACTH

Overview of Evidence

Author, year	Design/ sample size	Intervention & Comparison	Outcome
Zhang, 2014	Observational, n=60	IM betamethasone 7 mg x 1 vs diclofenac 75 mg BID x 7 days	Betamethasone > diclofenac pain reduction at day 3 Betamethasone = diclofenac pain reduction at day 7 Betamethasone< diclofenac adverse effects
Daoussis, 2013	Observational, n=181	IM ACTH 100 units	78% of patients improved after one day after a dose Minimal impact on blood pressure and serum potassium Elevation in fasting blood sugar for 24 hours
Terkeltaub, 2010	RCT, n=184	colchicine 1.8 mg total over 1 hour vs colchicine 4.8 mg total over 6 hours vs Placebo	Low-dose colchicine and high dose colchicine = comparable efficacy Low-dose colchicine safety profile = same as placebo
Man, 2007	RCT, n=90	prednisolone 30 mg/APAP 1g vs indomethacin 50 mg/APAP 1 g	Prednisolone/APAP is as effective as oral indomethacin/acetaminophen in relieving pain but ↓ adverse effects.
Siegel, 1994	RCT, n=31	IM adrenocorticotrophic hormone 40 IU vs IM triamcinolone acetonide 60 mg	Resolution of all symptoms occurred at an average of 8 days for both groups. No adverse reactions were noted in either group 11 reinjections in the ACTH group vs 5 reinjections in the triamcinolone acetonide group
Alloway, 1993	RCT, n=27	Indomethacin 50 mg TID Vs IM triamcinolone acetonide 60 mg	Resolution of all symptoms occurred at 8 days for a patient taking indomethacin vs 7 days with triamcinolone
Maccagno, 1991	RCT, n=61	etodolac 300 mg BID x 7 days vs naproxen 500 mg BID x 7 days	Significant in both treatment groups at each time intervals 93-97% of patients report improved condition treated with either agent

References

1. Micromedex [Electronic version].Greenwood Village, CO: Truven Health Analytics. Retrieved September 6, 2018, from <http://www.micromedexsolutions.com/>
2. Khanna D, et al. 2012 American College of Rheumatology guidelines for the management of gout. *Arthritis Care Res* 2012;64:1447-1461.
3. Wilson L, et al. *Pharmacotherapy*. 2016 Aug;36(8):906-22
4. Daoussis D, et al. *Joint Bone Spine*. 2013 May;80(3):291-4.
5. Terkeltaub RA, et al. *Arthritis Rheum*. 2010 Apr;62(4):1060-8
6. Man CY, et al. *Ann Emerg Med*. 2007 May;49(5):670-7.
7. Siegel LB, et al. *J Rheumatol*. 1994 Jul;21(7):1325-7.
8. Alloway JA, et al. *J Rheumatol* 1993; 20:111.
9. Maccagno A, et al. [Curr Med Res Opin](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1111111/). 1991;12(7):423-9.